ANI Pharmaceuticals, Inc. (ANIP)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
$73.16+2.02%
Close 2026-10-29 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
Research Workspace
Put ANIP beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 31% over the past year.
View GrowthMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskANIP’s generics execution and rare disease portfolio support growth, with recent revenue growth accelerating. Revenue grew 25.9% year over year in Q2 FY2026, versus 20.5% in Q1. Q2 FY2026 earnings beat consensus, while ANIP trades at 9.3× P/E versus the 15.7× peer median. The market is pricing more growth than our forecast, despite this peer discount. Management is running behind on a stated commitment, and our model puts next-quarter miss probability at 28%. Peer multiples imply a price about 35% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. ANIP is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering ANIP (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for ANIP in the last 4 months.
Continue this research
Compare ANIP with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ANIP Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put ANIP next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Continue strong Generics business execution and product launches
Generic launch supports product execution, but no scale or commercial impact is specified.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $73.16
The last 12 months of price, then the range of analyst 12-month targets from today’s $73.16.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Continue strong Generics business execution and product launches
FDA approval enhances generics business execution.
Advances: Expand Rare Disease portfolio and ILUVIEN growth
Deepening rare disease push aligns with management's growth objectives.
Advances: Expand Rare Disease portfolio and ILUVIEN growth
Rare disease portfolio expansion aligns with management's growth objectives.
Threatens: Increase Cortrophin Gel revenue
Quality control issues may hinder revenue growth.
Advances: Expand Rare Disease portfolio
Refocusing on rare diseases aligns with growth strategy.